<?xml version="1.0" encoding="UTF-8"?>
<p>Kaposi’s sarcoma-associated herpesvirus (KSHV), also named human herpesvirus 8 (HHV-8), is the etiologic agent of Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman’s disease (MCD) [
 <xref rid="ppat.1008156.ref001" ref-type="bibr">1</xref>,
 <xref rid="ppat.1008156.ref002" ref-type="bibr">2</xref>,
 <xref rid="ppat.1008156.ref003" ref-type="bibr">3</xref>]. KS is an endothelial-originated multicentric malignant neoplasm found in immunosuppressed patients, and most frequently in patients infected with HIV [
 <xref rid="ppat.1008156.ref001" ref-type="bibr">1</xref>,
 <xref rid="ppat.1008156.ref004" ref-type="bibr">4</xref>]. In contrast, PEL is a rare and aggressive B-cell non-Hodgkin's lymphoma that typically presents as a lymphomatous effusion without forming a solid mass [
 <xref rid="ppat.1008156.ref005" ref-type="bibr">5</xref>]. MCD is also a B-cell lineage disorder with specific characteristics of cytokine excess and viral lytic activation [
 <xref rid="ppat.1008156.ref006" ref-type="bibr">6</xref>]. Current therapeutics for KSHV-associated malignancies are not completely efficacious and have significant adverse side effects [
 <xref rid="ppat.1008156.ref007" ref-type="bibr">7</xref>,
 <xref rid="ppat.1008156.ref008" ref-type="bibr">8</xref>]. Therefore, the identification of more effective and safer anti-KSHV agents is urgently needed.
</p>
